Activity Description
In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer.
Target Audience
This activity has been designed to meet the educational needs of emergency medical physicians, nurses, and other clinicians involved in the management of patients with immune-related adverse events.
Educational Objectives
Upon completion of this activity, participants will be able to:
- Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology
- Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies
- Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED)
- Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED
- Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Providership, Credit, and Support
This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc., and PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.
Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Continuing Nursing Education
Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).
Faculty Disclosures
Co-Chairs
Evan J. Lipson, MD
Associate Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
Bloomberg~Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Baltimore, Maryland
Evan J. Lipson, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Sysmex. All research funding goes to institution.
Consultant and/or Advisor for Array BioPharma; Bristol-Myers Squibb; EMD Serono, Inc.; MacroGenics, Inc.; Merck & Co., Inc.; and Millennium.
Andrew Stolbach, MD, MPH
Medical Toxicologist
Emergency Physician
Associate Professor, Department of Emergency Medicine
Johns Hopkins University School of Medicine
Johns Hopkins Hospital
Baltimore, Maryland
Andrew Stolbach, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee Disclosures
Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, MLI, has nothing to disclose.
The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.
Content/Peer Reviewer Disclosures
The following Content/Peer Reviewers have nothing to dislose:
Gina D. Cravey, BSN, RN, CHRC, CCRC
Matthew A. Goodman, MD
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@peerview.com.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
About This CME/MOC/CNE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2019, PeerView